Navigation Links
Breast Enlightenment Presents Breast Angel, the First Home Care Breast Health System, to Prevent Breast Cancer
Date:2/15/2011

WHITE PLAINS, N.Y., Feb. 15, 2011 /PRNewswire/ -- Now, with your own personal Breast Angel in hand, through the science of trans-dermal illumination, you are going to be able to actually see inside your breasts. With routine monthly use, you will learn to discern exactly what your normal internal physiological appearance is, and more importantly, what is not. Your monthly breast self-exams no longer have to be a dreaded procedure nor a confusing one. Interpreting your result is easy, especially for those with fibrocystic conditions.

A harmless clear fluid-filled cyst will allow the light beam of Breast Angel to pass through uninterrupted while potentially dangerous conditions will absorb the light, becoming opaque and casting a dark spot. It is that simple.

The U.S. Preventive Services Task Force revised their recommendations for breast cancer screenings in the USA. It advised that instead of age forty, females are to wait until age fifty for their first mammogram, and should repeat their mammograms at two-year instead of yearly intervals.

In her research, Lisa LoCascio, president of BUST LLC, discovered that her female counterparts all over the world are far more proactive as healthcare advocates, particularly when it comes to protecting themselves from breast cancer.

Breast Angel is Lisa's premier product, and she is so happy to know we are going to keep you healthy together. Her online program will provide you with support as well as remind you when it is time for your monthly exam.

Remember, Lisa does not ever, ever want you to fight breast cancer ...just prevent it.

Website: http://www.breastenlightenment.com/

Extreme Marketing and Consulting New York is your EXTREME source for extreme Internet marketing, Internet advertising, publicity and online reputation management for small businesses. For further information, please contact us at (914) 316-9486 or at http://www.ExtremeOnlineMarketingSolutions.com.

This press release was issued through 24-7PressRelease.com.  For further information, visit http://www.24-7pressrelease.com.


'/>"/>
SOURCE Breast Enlightenment
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
Breaking Medicine News(10 mins):